J. E. Meca-Lallana:
ORCID: https://orcid.org/0000-0001-5050-9890
Role: InvestigationRole: Writing – review & editing
C. Oreja-Guevara:
ORCID: https://orcid.org/0000-0002-9221-5716
Role: ConceptualizationRole: InvestigationRole: MethodologyRole: SupervisionRole:
Writing – review & editing
D. Muñoz: Role: InvestigationRole: Writing – review & editing
J. Olascoaga: Role: InvestigationRole: Writing – review & editing
A. Pato: Role: InvestigationRole: Writing – review & editing
L. Ramió-Torrentà: Role: InvestigationRole: Writing – review & editing
V. Meca-Lallana: Role: InvestigationRole: Writing – review & editing
M. A. Hernández: Role: InvestigationRole: Writing – review & editing
M. E. Marzo: Role: InvestigationRole: Writing – review & editing
J. C. Álvarez- Cermeño: Role: InvestigationRole: Writing – review & editing
A. Rodríguez-Antigüedad: Role: ConceptualizationRole: InvestigationRole: MethodologyRole: SupervisionRole:
Writing – review & editing
X. Montalbán: Role: ConceptualizationRole: InvestigationRole: MethodologyRole: SupervisionRole:
Writing – review & editing
O. Fernández:
ORCID: https://orcid.org/0000-0003-3696-789X
Role: ConceptualizationRole: InvestigationRole: MethodologyRole: SupervisionRole:
Writing – original draftRole: Writing – review & editing
Aristeidis H. Katsanos: Role: Editor
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS One
Journal ID (publisher-id): plos
Title:
PLoS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
13
October
2021
Publication date Collection: 2021
Volume: 16
Issue: 10
Electronic Location Identifier: e0258437
Affiliations
[1
]
Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia,
Spain
[2
]
Neurology Department, Hospital Clínico San Carlos, Madrid, Spain
[3
]
Neurology Department, Hospital Xeral de Vigo, Vigo, Spain
[4
]
Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain
[5
]
Neurology Department, Hospital Povisa, Vigo, Spain
[6
]
Neurology Department, Hospital Universitari de Girona Dr. Josep Trueta, IDIBGI; Medical
Sciences Department, University of Girona, Girona, Spain
[7
]
Neurology Department, Hospital Universitario de La Princesa, Madrid, Spain
[8
]
Neurology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz
de Tenerife, Spain
[9
]
Hospital San Pedro, Logroño, Spain
[10
]
Neurology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
[11
]
Neurology Department, Hospital Universitario Cruces, Barakaldo, Spain
[12
]
Neurology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain
[13
]
Department of Pharmacology, Faculty of Medicine, Universidad de Málaga; Instituto
de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
University of Ioannina School of Medicine, GREECE
Author notes
Competing Interests: Meca‐Lallana [Biogen, Genzyme, Merck Serono, Novartis, Roche and TEVA], C. Oreja‐Guevara
[Biogen‐Idec, Novartis, Merck‐Serono, Almirall, Teva and Genzyme], D. Muñoz [Merck,Biogen,
Teva, Novartis and Genzyme], J. Olascoaga [Biogen Idec, Bayer‐Schering, Genzyme, Merck‐Serono,
Novartis and Teva], A. Pato [Novartis, Biogen and Genzyme Almirall], L. Ramió [Biogen
Idec, Novartis, Bayer, Merck‐Serono, Genzyme, Teva PharmaceuticalIndustries Ltd.],
V. Meca‐Lallana [Almirall, Biogen Idec,Genzyme, Merck Serono, Novartis, Roche, Teva
and Terumo], M.A. Hernández [Merck Serono, Novartis, Biogen, Genzyme, TEVA and Almirall
], M.E. Marzo [nothing to disclose ], J.C. Álvarez‐Cermeño [Bayer Schering Pharma,
Merk Serono, Biogen‐Idec, Teva Pharmaceuticals, Sanofi‐Aventis, Genzyme, and Novartis
], A. Rodríguez‐Antigüedad [Biogen‐Idec, Novartis, Merck‐Serono, Teva and Genzyme.
], X. Montalbán [Biogen‐Idec, Bayer‐ Schering, Merck‐Serono, Teva, Novartis, and Sanofi‐Genzyme,
Bayer‐Schering, Genzyme, Merck‐Serono, Teva, Novartis, Actelion, Almirall, Allergan
and Roche.] Ó. Fernández [Biogen‐Idec, Bayer‐ Schering, Genzyme, Merck‐Serono, Teva,
Novartis, Actelion, Almirall, Allergan and Roche.] The rest of investigators do not
declare any competing interests related to this article.
¶ The complete membership of the author group can be found in the Acknowledgments
Author information
Article
Publisher ID:
PONE-D-21-19084
DOI: 10.1371/journal.pone.0258437
PMC ID: 8513911
PubMed ID: 34644366
SO-VID: 274d5c83-cdf9-4dac-803a-bd3beb7e64e2
Copyright © © 2021 Meca-Lallana et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funded by:
Academia Española de Esclerosis Múltiple y Otras Enfermedades Autoinmunes (ACADEM)
Award ID: Novartis
The study was funded by the Academia Española de Esclerosis Múltiple y Otras Enfermedades
Autoinmunes (ACADEM), with a restricted investigational grant form Novartis. The funder
had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Subject:
Research Article
Subject:
Biology and Life Sciences
Subject:
Biochemistry
Subject:
Proteins
Subject:
Interferons
Subject:
Medicine and Health Sciences
Subject:
Clinical Medicine
Subject:
Signs and Symptoms
Subject:
Lesions
Subject:
Medicine and Health Sciences
Subject:
Clinical Medicine
Subject:
Clinical Immunology
Subject:
Autoimmune Diseases
Subject:
Multiple Sclerosis
Subject:
Biology and Life Sciences
Subject:
Immunology
Subject:
Clinical Immunology
Subject:
Autoimmune Diseases
Subject:
Multiple Sclerosis
Subject:
Medicine and Health Sciences
Subject:
Immunology
Subject:
Clinical Immunology
Subject:
Autoimmune Diseases
Subject:
Multiple Sclerosis
Subject:
Medicine and Health Sciences
Subject:
Medical Conditions
Subject:
Demyelinating Disorders
Subject:
Multiple Sclerosis
Subject:
Medicine and Health Sciences
Subject:
Neurology
Subject:
Demyelinating Disorders
Subject:
Multiple Sclerosis
Subject:
Medicine and Health Sciences
Subject:
Medical Conditions
Subject:
Neurodegenerative Diseases
Subject:
Multiple Sclerosis
Subject:
Medicine and Health Sciences
Subject:
Neurology
Subject:
Neurodegenerative Diseases
Subject:
Multiple Sclerosis
Subject:
People and Places
Subject:
Population Groupings
Subject:
Ethnicities
Subject:
European People
Subject:
Spanish People
Subject:
People and Places
Subject:
Population Groupings
Subject:
Ethnicities
Subject:
Hispanic People
Subject:
Spanish People
Subject:
Medicine and health sciences
Subject:
Clinical medicine
Subject:
Clinical trials
Subject:
Phase III clinical investigation
Subject:
Medicine and health sciences
Subject:
Pharmacology
Subject:
Drug research and development
Subject:
Clinical trials
Subject:
Phase III clinical investigation
Subject:
Research and analysis methods
Subject:
Clinical trials
Subject:
Phase III clinical investigation
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Adverse Reactions
Subject:
Medicine and Health Sciences
Subject:
Clinical Medicine
Subject:
Signs and Symptoms
Subject:
Lymphopenia
Subject:
Research and Analysis Methods
Subject:
Research Design
Subject:
Clinical Research Design
Subject:
Adverse Events
